

Remarks

Upon entry of the above amendment, claims 1-7, 8-16 and 24 will pending in the present application. Applicants have canceled claims 8, 17-23 and 25-27 without prejudice to the subject matter contained therein. Applicants have not raised any issue of new matter.

Election/Restriction

Applicants elected Group I, claims 1-16 and 24-27 in a previous response filed on November 13, 2006. Applicants again acknowledge the election.

The Examiner has stated that the elected subject matter has been broadened to all compounds and compositions of formula (I) wherein X and Y are each -CH-. The original full scope of all other variables has been examined.

Issue Under 35 U.S.C. §112

Claim 25 stands rejected under 35 U.S.C. §112, first paragraph as alleged failing to comply with the written description requirement and failing to have a specification that enables the entire scope.

Applicants traverse the Examiner's assertion; however, to expedite prosecution, Applicants have canceled claim 25. Applicants reserve the right to file a Continuation Application directed to the subject matter of claim 25.

Objections to the Claims

Claims 26 and 27 stand rejected as being substantial duplicates of claim 24. Applicants have canceled claims 26 and 27.

Claims 1-5, 7, 8 and 16 stand objected to as containing non-elected subject matter. Applicants respectfully submit that the amendment to the claims have removed the non-elected subject matter from the claims.

Claims 2-16 and 24-27 stand rejected as depending from rejected to or objected to claims. Applicants have amended the claims or canceled the claims that the Examiner has raised issues.

Applicants respectfully submit that the claims as amended are in good condition for allowance.

Conclusion

Applicants have addressed each issue presented in the outstanding Office Action and overcame the issue or rendered the issue moot.

If the Examiner feels that communication by telephone could expedite the Allowance of the instant application, the examiner is invited to contact the undersigned at (617) 871-4125 in Cambridge, MA.

The commissioner is hereby authorized to charge any additional fees that may be due, or to credit any overpayment, to Account number 19-0134. Applicants respectfully submit that the present claims are in condition for allowance.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(617) 871-4125


Mark W. Milstead
Agent for Applicant
Reg. No. 45,825

Date: May 11, 2007